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Abstract
Introduction: Ensuring equitable coverage of appropriate malaria treatment remains a high priority for the Nigerian
government. This study examines the health seeking behaviour, patient-provider interaction and quality of care
received by febrile patients of different socio-economic status (SES) groups.
Methods: A total of 1642 febrile patients and caregivers exiting public health centres, pharmacies and patent medicine
dealers were surveyed in Enugu state, South-East Nigeria to obtain information on treatment seeking behaviour,
patient-provider interactions and treatment received. Socioeconomic status was estimated for each patient using exit
survey data on household assets in combination with asset ownership data from the 2008 Nigeria Demographic and
Health Survey.
Results: Among the poorest SES group, 29% sought treatment at public health centres, 13% at pharmacies and 58% at
patent medicine dealers (p < 0.01). Very few of those in the richest SES group used public health centres (4%) instead
choosing to go to pharmacies (44%) and patent medicine dealers (52%, p < 0.001). During consultations with a
healthcare provider, the poorest compared to the richest were significantly more likely to discuss symptoms with
the provider, be physically examined and rely on providers for diagnosis and treatment rather than request a
specific medicine. Those from the poorest SES group were however, least likely to request or to receive an
antimalarial (p < 0.001). The use of artemisinin combination therapy (ACT), the recommended treatment for
uncomplicated malaria, was low across all SES groups.
Conclusions: The quality of malaria treatment is sub-optimal for all febrile patients. Having greater interaction
with the provider also did not translate to better quality care for the poor. The poor face a number of significant
barriers to accessing quality treatment especially in relation to treatment seeking behaviour and type of treatment
received. Strategies to address these inequities are fundamental to achieving universal coverage of effective malaria
treatment and ensuring that the most vulnerable people are not left behind.
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Background
Artemisinin Combination Therapy (ACT) has been the
first line recommended medicine for uncomplicated
malaria in Nigeria since 2005 and government treatment
guidelines recommend that all febrile patients should be
presumptively treated with this drug when malaria
testing is not available [1]. The Nigerian government has
also implemented initiatives designed to improve cover-
age, availability and uptake of effective malaria treat-
ment; these initiatives include home management of
malaria through training of community health workers,
and supplying ACT without charge to pregnant women
and children under-five attending primary health facil-
ities [2].
Differential treatment seeking for malaria in South-
East Nigeria has been reported through a number of
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household surveys [3-6]. These studies have found that
those from poorer households attend low level and in-
formal providers, or may not seek treatment at all
[4,7,8]. These low level providers have often been associ-
ated with substandard practices including poor counsel-
ling, incorrect dosing, misdiagnosis and the use of less
effective drugs [9,10]. While these studies offer an over-
all description of treatment seeking for febrile illness,
little detail is known about the reasons for choice of
treatment providers and the quality of care obtained
for uncomplicated malaria across socioeconomic status
groups. Given the present efforts by government and
non-governmental agencies to subsidise ACT in both
public and private provider outlets [11], it is important
to understand the extent to which individuals of different
socioeconomic status (SES) receive these antimalarials.
Quality of care is closely intertwined with treatment
seeking behaviour and perceptions of quality can influ-
ence patterns of treatment seeking [12]. Quality of care
as a concept has been defined in different dimensions
and its elements described along the structure-process-
outcome continuum [13,14]. While structural measures
relate to those of the physical environment, process fo-
cuses on what happens in the interaction between the
patient and the provider and outcomes typically include
the consequences of care [14]. Each of these dimensions
is known to be important in the context of malaria
[15-17] but few have explored this in relation to SES
[18]. The process of care, in particular the patient-
provider interaction, is the least well understood in the
context of febrile illness and merits more enquiries due
to its potential influence on the outcomes of care [19].
Enhanced patient-provider interaction is characterised
by extended dialogue which enables patients to disclose
vital information about their health problems and pro-
viders to make more accurate diagnoses [19,20]. It pro-
vides the enabling context within which the information
about the treatment regimen is communicated, which in
turn can foster adherence to regimen and ultimately lead
to better care outcomes [20,21]. These outcomes could
be reflected in the type of treatment received, reduction
of patient’s symptoms and recovery [21]. Studies show
that poor patient provider interaction often arises from
the existence of differential educational, socio-economic
and cultural backgrounds as well as language barriers
and environmental factors [22]. Individual and health
system related constraints including lack of communica-
tion skills on the part of either the provider or the patient
[23], high workload, and staff shortages, play prominent
roles in provider-patient interaction [24]. Understanding
the patient-provider interaction and the outcomes of the
interaction can provide useful insight into the aspects of
care process that influence delivery of quality malaria treat-
ment to patients of different socioeconomic status.
This paper focuses on the patient-provider interaction
and the outcomes of these interactions across SES
groups. Data collected from patients or their caregivers
as they exit public health centres, pharmacies and patent
medicine dealers (PMDs) is used to describe inequities
in treatment seeking, including the reasons for choice of
treatment providers, detail of the interactions that took
place between patient and provider and type of treat-
ment received. The findings from this study provide
insight into the type of interventions needed for achiev-
ing improvement in quality and coverage of effective
malaria treatment.
Methods
Study setting
Formative research was undertaken in Enugu state,
south-east Nigeria, to inform the selection and design of
interventions to improve diagnosis and treatment of
malaria among febrile patients attending public and pri-
vate sector providers. This study has been described in
detail elsewhere [25]. In summary, the study was under-
taken in Udi, a rural local government area (LGA)
and urban areas of Enugu (comprising Enugu East,
Enugu South and Enugu North LGAs) between July and
December 2009. Malaria is endemic in both sites and oc-
curs throughout the year, but peaks around September to
October during the rainy season. The study sites are
similar in terms of language and culture. The study was
undertaken at primary health centres (PHC) (which
comprises of public health centres, health posts and
dispensaries), pharmacies and patent medicine dealers
(PMDs) also known as private medicine retailers. PHC
facilities are usually staffed by community health officers,
community health extension workers and less often
nurses and midwives, and at these facilities treatment of
uncomplicated malaria with an ACT is free of charge for
pregnant women and children. Licensed pharmacists
manage pharmacy shops where they dispense and sell
pharmaceutical products as well as provide advice to pa-
tients [26]. PMDs are licensed to sell over the counter
drugs and are a major source of malaria treatment [27].
There are no legal requirements about the education or
training of PMDs, and it is accepted that they have a
commercial role. At pharmacies and PMDs, patients pay
the full cost of drugs. ACT was introduced to the study
site in 2005 and over three-quarters (80%) of facilities
were reported to have ACT in stock at the time of this
study [25].
Study design
A multi-stage cluster survey was conducted in 16 (8
communities in each site) randomly selected communi-
ties, stratified by type of facility. All PHCs in the com-
munities were included due to their small number while
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pharmacies and PMDs were randomly selected with
probability proportionate to size assuming that a total of
80 facilities could be visited. Respondents were febrile
patients of all ages or their caregivers visiting the se-
lected facilities during the period of the survey (July to
December, 2009). Written consent from patients and
caregiver was sought before determining their eligibility
to participate in the survey. An individual was consid-
ered eligible if s/he reported seeking treatment for a
fever or if s/he had received an ACT, were older than
6 months, and not pregnant. Individuals who were exit-
ing a facility were assessed in turn until the patient
quota of 20 patients per PHC and 14 per pharmacy and
PMD was reached. These sample sizes per facility were
determined for the primary study outcome, proportion
of febrile patients receiving the recommended treatment
for malaria [25].
Data collection
Data were collected from eligible respondents as they
exited the facility if they had given consent. Treatment
may be sought for oneself, a child or another person
who is not present (the latter applies only at pharmacies
and PMDs). Information was obtained on general demo-
graphic details, previous treatment seeking for the illness
episode, reasons for the choice of provider, and nature
of interaction with the provider, including whether the
provider was told about the patients’ symptoms, whether
the patient was physically examined, was tested for
malaria, as well as the treatment received. Respondents
were also asked about asset ownership in their house-
hold (including source of drinking water, type of cooking
fuel, toilet facilities and building materials). These ques-
tions on asset ownership were identical to those in the
National Demographic and Health Survey conducted in
Nigeria in 2008 [28].
Statistical analysis
There were two parts to the statistical analysis. The first
part of the analysis focused on the measurement of so-
cioeconomic status. This involved comparing asset own-
ership of patients to the asset ownership of individuals
living in comparable areas in South-East Nigeria (from
the Demographic and Health Survey, DHS) [28]. This
was possible since the questions on asset ownership
were the same as those that the DHS asked of survey
respondents. This approach was adopted in order to de-
scribe the SES of patients with reference to the local
population (rather than relative to the sub-group that
sought treatment).The approach used principal compo-
nents analysis to compute weights for the ownership of
a defined list of assets using DHS data collected in urban
areas of South-East Nigeria in 2008 [29,30]. A wealth
score was generated for individuals in the DHS data set,
where the wealth score is the sum of the weights for
those assets that an individual owns. Individuals in the
DHS population were then ranked by their wealth score
and divided into five groups, and this determined the
cut-off values of the wealth score for each quintile. The
next step was to estimate the wealth scores of each pa-
tient in the exit survey, using the weights derived from
the DHS population. Patients were then assigned to one
of the socioeconomic quintiles based on their wealth
score and the previously determined cut-off values [29].
DHS data was selected to be representative of the local
population, though we acknowledge differences in the
geographic areas and timing of data collection. As there
were relatively few exit survey respondents from the
poorest 40% of the population the poorest two quintiles
were combined into one SES group. The SES groups
were then poorest quintile (Q1 and Q2), 3rd quintile
(Q3), 4th quintile (Q4) and richest quintile (Q5).
The second part involved describing patient character-
istics and geographic distribution as well as treatment
seeking behaviour, health care interaction and treatment
received. Specific variables used to describe treatment
seeking behaviour included the timing of treatment seek-
ing, type of provider visited and reasons for the choice
of provider. For describing the patient-provider inter-
action, variables included whether the patient told the
health worker about symptoms, whether health worker
asked follow up questions about patients illness, physic-
ally examined patient, took patients’ temperature, tested
patient for malaria and whether patient requested a spe-
cific medicine. Variables to describe outcome were the
type of treatment received and whether patients received
an ACT in the correct dose and knew the regimen [25].
Relative to the local population, the patient exit data
were analysed by SES group to describe the study popu-
lation, treatment seeking behaviour, and health care
interaction including treatment received. The percent-
ages reported are population-average estimates, which
have been adjusted for the study design by identifying
different probabilities of selection, clustering and stratifi-
cation [30]. Outcomes by SES group were compared
using the Rao and Scott chi-squared correction [30].
Ethical approval
Ethical approval for this study was obtained from the
University of Nigeria ethics review board (UNTH/
CSA.329) and London School of Hygiene and Tropical
Medicine, UK (approval 5429).
Results
Data were collected from 100 health facilities using a pre-
tested interviewer-administered questionnaire and the ana-
lysis is based on exit data collected from 1642 patients,
having excluded 33 pregnant women and 28 children
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under six months that did not meet the eligibility criteria.
Characteristics of patients included in the study are pre-
sented in Table 1. Significant variations in all characteristics
(except gender) were observed between the SES groups.
Those patients from the poorest quintile were more likely
to reside in a rural location (p < 0.001), be less than 5 years
(p = 0.005), and have a lower level of education (or with a
caregiver with a lower level of education if the patient was
a child) (p < 0.001).
Inequities in treatment seeking behaviour
Around half (47%) of those patients seeking treatment
were from the richest 20% of the population, while about
one in ten patients were from the poorest 40% of the
population. There was evidence that a significantly lon-
ger duration had elapsed between onset of symptoms
and presentation at health facilities for treatment among
those in the poorest SES groups, compared to richer
SES groups (p = 0.044). Those in the poorer SES groups
were however more likely to have previously sought
treatment for their current illness prior to seeking treat-
ment at the study facilities (p = 0.002). Of the 469 pa-
tients who had previously sought treatment, most had
done so at a PMD across all SES groups though the
richer SES groups also sought treatment at pharmacies
(p = 0.006). Only 6% received an ACT in their previous
treatment while 39% received an antimalarial (no signifi-
cant difference across SES group) (Table 2).
For current treatment, PMDs were again widely used
by all SES groups, though PHC facilities were also
frequently used by those of lower SES while pharmacies
mostly served those from richer SES (p < 0.001). Those
in the poorest SES groups were more likely to travel fur-
ther to seek treatment (p < 0.001) (Table 2).
With respect to reasons for the choice of provider, pro-
viders’ reputation, cost and staff qualifications/experience
were important determinants that differed significantly be-
tween the SES groups. Provider reputation was more likely
to be a consideration for those in richer SES groups
(p = 0.002) while qualification of staff (p = 0.022) and
cost of treatment were more often noted by those from the
poorer SES groups (p = 0.021).
Inequities in the patient-provider interaction and
treatment received
Significant differences were revealed in the nature of
patient-provider interaction, with those of lower SES
more reliant on the provider to diagnose their illness.
For example, the poorest were more likely to have told
the provider about their symptoms (p < 0.001), be asked
follow up questions about their illness (p = 0.011),
undergo a physical examination (p = 0.031), and have
their temperature taken (p = 0.007). Across all SES groups
less than 1% of patients were tested for malaria using either
microscopy or RDT.
About 79% of patients seeking treatment for a fever
received an antimalarial and the proportion differed sig-
nificantly by SES (p < 0.001). About 22% received an
ACT and 40% received SP, a smaller number, 13% re-
ceived monotherapy and about 50% received an antipyretic
Table 1 Characteristics of patients for whom treatment was sought*
Poorest 40% Third 20% Fourth 20% Richest 20% All P-value
n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]*
N = 362 N = 292 N = 423 N = 565 N = 1642
Area of residence
Enugu (urban) 54 (30.9) [19.2-45.8] 150 (79.4) [70.3-86.3] 346 (93.1) [88.85.8] 512 (96.6) [94.0-98.1] 1062 (87.9) [85.2-90.2] <0.001
Udi (rural) 308 (69.1) [54.2-80.8] 142 (20.6) [13.8-29.7] 77 (7.0) [4.3-11.2] 53 (3.4) [1.9-6.0] 580 (12.1) [9.8-14.8]
Gendera
Male 161 (45.2) [36.3-54.5] 140 (53.4) [40.0-66.5] 228 (55.5) [46.0-64.5] 313 (57.9) [51.1-64.4] 842 (55.5) [51.7-59.3] 0.482
Female 195 (54.8) [45.5-63.7] 147 (46.6) [33.5-60.2] 191 (44.5) [35.5-48.9] 245 (42.1) [35.6-48.9] 778 (44.5) [40.8-48.3]
Age group
>15 yrs 196 (64.0) [54.5-72.5] 176 (71.4) [63.2-78.4] 319 (83.8) [76.7-89.0] 407 (75.8) [69.6-81.1] 1098 (76.7) [72.44-80.5] 0.005
5 to 15 yrs 69 (17.2) [12.4-23.3] 50 (13.8) [8.7-21.1] 46 (8.0) [5.1-12.3] 79 (14.4) [10.6-19.2] 244 (12.5) [10.1-15.5]
<5 yrs 97 (18.8) [12.5-27.4] 66 (14.8) [8.9-23.6] 58 (8.2) [4.7-14.0] 79 (9.8) [6.7-14.0] 300 (10.7) [8.1-14.0]
Education level of patient (or caregiver)b
Primary 195 (52.3) [43.4-61.1] 86 (29.4) [20-8-39.9] 54 (12.1) [8.0-17.8] 45 (7.3) [4.5-11.5] 380 (15.4) [12.4-18.9] <0.001
Secondary 132 (41.5) [32.8-50.9] 140 (41.8) [31.7-52.6] 192 (43.8) [35.0-53.0] 218 (37.2) [29.9-45.1] 682 (40.2) [34.9-45.7]
Tertiary 18 (6.2) [2.4-15.2] 57 (28.8) [21.4-37.5] 171 (44.1) [35.3-53.4] 292 (55.6) [47.2-63.8] 538 (44.5) [38.9-50.1]
*Population averaged percentages which have been adjusted for the survey design.
Notes: (a)missing 22 responses; (b)missing 42 responses.
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no significant differences were observed in these results
across SES.
Those in the richer SES groups were more likely to re-
ceive an antimalarial (p < 0.001) and to have requested a
specific medicine from the provider (p < 0.001) with
those from the lower SES groups more dependent on
the provider to recommend medicines. About 61% of all
patients reported asking for a specific medicine during
Table 2 Inequalities in treatment seeking behaviour
Poorest 40% Third 20% Fourth 20% Richest 20% All P-value
n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]*
N = 362 N = 292 N = 423 N = 565 N = 1642
Number of days since start of symptomsc
Same day 31 (11.4) [5.6-22.1] 51 (27.2) [16.6-41.3] 77 (24.2) [17.4-32.8] 89 (17.8) [13.5-22.9] 248 (20.6) [16.1-25.9]
1 day 61 (16.3) [(9.8-25.8] 64 (22.4) [15.6-31.0] 82 (17.2) [10.9-26.0] 123 (22.9) [16.6-30.6] 330 (20.5) [16.0-25.9] 0.044
2 days 61 (15.0) [9.5-22.8] 54 (19.3) [11.5-30.7] 80 (21.6) [16.1-28.4] 126 (21.1) [17.9-27.2] 321 (21.1) [18.1-24.4]
3-5 days 121 (33.4) [24.7-43.5] 93 (24.8) [17.2-34.2] 118 (23.6) [16.8-32.0] 154 (25.3) [19.6-31.6] 486 (25.3) [21.2-29.7]
6+ days 88 (23.9) [16.2-33.8] 29 (6.4) [3.1-12.6] 64 (13.4) [8.4-20.7] 73 (12.6) [8.6-16.6] 254 (12.6) [9.3-16.9]
First time treatment was sought for illness episoded
Yes 202 (60.7) [51.3-69.4] 192 (80.9) [69.8-88.6] 327 (82.9) [74.9-88.7] 444 (81.2) [75.8-85.7] 1165 (80.1) [75.2-84.2] 0.002
No 160 (39.3) [30.7-48.7] 98 (19.1) [11.4-30.2] 93 (17.1) [11.3-25.1] 118 (18.8) [14.3-24.2] 469 (19.9) [15.8-24.9]
Of those that previously sought treatment for this illness episode what type of provider was visited?
Public hospital 13 (9.0 [2.7-26.4] 9 (13) [3.2-40.2] 4 (1.0) [0.2-5.2] 10 (9.4) [3.4-23.3] 36 (7.6) [3.5-15.5] 0.006
Primary health facility 15 (5.6) [3.0-10.2] 5 (3.5) [1.5-8.0] 11 (7.5) [2.7-18.8] 7 (1.2) [0.4-3.5] 38 (4.0) [2.2-7.2]
Pharmacy 3 (6.0) [0.8-33.5] 3 (3.0) [0.6-14.4] 14 (19.7) [7.0-44.3] 31 (37.0) [25.2-50.6] 51 (22.5) [14.4-33.4]
Patent medicine dealer 94 (62.7) [45.7-77.0] 53 (57.0) [39.9-72.5] 49 (57.3) [36.9-75.5] 38 (36.3) [25.2-50.6] 234 (49.1) [38.8-59.5]
Other 32 (16.7) [8.5-30.0] 25 (23.5) 10.0-45.7] 12 (14.6) [6.9-28.2] 22 (16.1) [9.2-26.8] 91 (16.8) [11.8-23.4]
Of those that previously sought treatment, what treatment was obtained? (n = 469)
Any AM 43 (27.4) [16.5-42.0] 30 (29.3) [17.1-45.6] 39 (43.9) [28.7-60.3] 48 (43.0) [27.9-59.6] 160 (38.9) [29.7-49.1] 0.265
ACT 6 (2.7) [1.1-6.6] 1 (1.0) [0.3-3.1] 9 (9.8) [3.2-27.0] 6 (5.8) [1.8-17.1] 22 (5.8) [2.6-12.4] 0.160
Antipyretic 78 (39.4) [27.4-52.8] 51 (43.4) [29.8-58.4) 46 (42.8) [30.3-56.2] 59 (49.7) [35.9-63.4] 234 (45.4) [37.2-53.9] 0.581
Antibiotic 14 (7.0) [3.7-12.8] 10 (10.6) [2.8-32.9] 5 (4.5) [1.1-16.9] 9 (7.0) [2.4-18.8] 38 (6.8) [3.5-12.6] 0.715
Type of provider for current treatment
Public facility 144 (28.8) [19.6-40.2] 116 (13.5) [9.2-19.5] 103 (5.5) [4.4-7.2] 103 (4.3) [2.3-8.0] 466 (7.9) [6.5-9.5] <0.001
Pharmacy 14 (13.0) [4.8-30.5] 38 (23.8) [10.8-44.5] 111 (34.1) [17.5-55.7] 199 (44.0) [27.4-62.1] 362 (35.6) (21.9-52.2]
Patent Medicine Dealer 204 (58.3) [43.4-71.7] 138 (62.7) [42.4-79.3] 209 (60.4) [39.5-78.1] 263 (51.8) [34.2-68.9] 814 (56.5) [40.6-71.1]
Reasons given for the choice of providere
Have used before 263 (67.0) [55.4-76.9] 178 (52.7) [35.4-69.3] 218 (47.3) [37.2-57.5] 316 (57.1) [48.7-65.1] 975 (54.2) [46.7-61.6] 0.103
Convenient location 155 (43.6) [32.8-55.1] 154 (59.3) [45.4-71.8] 238 (61.1) [52.1-69.3] 299 (52.5) [43.9-61.0] 846 (55.4) [48.9-61.8] 0.1041
Good reputation 100 (26.0) [18.6-35.1] 110 (43.6) [30.3-57.9] 187 (46.4) [38.4-54.7] 277 (54.2) [45.1-63.0] 674 (48.1) [40.5-55.7] 0.002
Availability of drugs 126 (33.5) [23.2-45.8] 116 (41.8) [30.4-54.1] 202 (48.9) [34.5-63.5] 231 (48.8) [37.2-60.6] 675 (46.7) [37.4-56.6] 0.280
Inexpensive 111 (27.5) [19.3-37.5] 86 (21.5) [14.8-30.2] 94 (15.1) (9.2-24.0) 93 (12.8) [8.8-18.3] 384 (15.9) [12.1-20.7] 0.021
Qualification of staff 65 (13.9) [7.5-24.3] 79 (17.6) [9.4-30.6] 97 (19.3 (11.6-30.3) 65. (9.2) [5.4-15.3] 306 (13.9) [9.4-20.1] 0.022
Travel time (minutes)f
0-15 149 (46.3) [35.6-57.4] 169 (74.2) [63.4-82.6] 290 (82.2) [73.7-88.4] 395 (76.1) [68.6-82.2] 1003 (75.3) [69.7-80.1] <0.001
16-30 107 (27.6) [20.3-36.4] 64 (16.4) [10.6-24.5] 67 (12.6) [7.6-20.3] 110 (17.1) [11.9-24.0] 348 (16.5) [12.7-21.1]
31-45 39 (9.3) [5.1-16.3] 24 (5.2) [1.8-14.0] 23 (3.5) [1.7-7.1] 23 (4.5) [2.2-8.9] 109 (4.6) (3.1-7.0]
46-60 22 (6.2) [3.6-10.4] 13 (2.8) [1.0-7.0] 6 (0.4) [0.2-1.0] 12 (1.5) [0.6-3.9] 53 (1.7) [1.1-2.8]
>60 32 (10.7) [4.2-24.5] 6 (1.5) [0.3-8.0] 10 (1.3) [0.4-4.2] 5 (0.8) [0.2-3.6] 53 (1.9) [0.9-3.7]
*Population averaged percentages and corresponding 95% confidence intervals, which have been adjusted for the survey design.
Notes: (c)missing 3 responses; (d)missing 8 responses (e)unprompted and multiple responses were possible; (f)missing 15 responses.
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their interaction with a provider, with 89% requesting an
antimalarial and 25% requesting an ACT. There was no
significant difference across SES groups in the type of
medicine requested or the type of treatment received.
More than half of those receiving an ACT across all SES,
did so in the correct dose (p = 0.716) and knew the treat-
ment regimen (p = 0.655), but there were no significant
variations by SES (Table 3).
Discussion
This paper has presented new information about inequi-
ties in the nature of health care interaction and quality
of treatment received for febrile illness in South-East
Nigeria. Several inequities in treatment seeking for fe-
brile illness were identified in this study. The interval be-
tween the onset of symptoms and treatment seeking was
significantly greater in the poorest SES group compared
to the richest; the poor were also less likely to be seeking
treatment for the first time which suggests that previous
treatment may have been ineffective. The finding that
the poor were more likely than the rich to attend public
facilities rather than pharmacies was consistent with re-
ported reasons for choice of provider. For the poorest,
the choice of provider was heavily influenced by cost.
Public facilities offer malaria treatment at no cost for
pregnant women and children while private facilities
charge higher prices compared to public facilities [31].
These patterns of treatment seeking are contrary to what
has been reported in earlier studies in South-East
Nigeria where the poor were found to use lower level
providers (traditional healers, PMDs) while the rich re-
lied more heavily on public facilities [7]. Though this dif-
ference may be partly explained by the age profile of
patients since the proportion of children attending pub-
lic facilities was significantly higher among the poorest
SES group [25].
There were also important differences in the nature of
the patient-provider interaction across socioeconomic
groups. Differential health care interactions have been
reported elsewhere suggesting a tendency for providers
to have better interactions with those of higher SES [32]
due to the presumption that the poor are less well edu-
cated and thus less able to understand the information
given by the provider. In contrast, we found that those
in the lower SES groups were more likely to discuss
symptoms with providers, be examined and rely on the
provider to recommend treatment. However, this is
likely to be influenced by the fact that it was more com-
mon for the lower SES groups to seek treatment at pub-
lic facilities. In other words, some of these differences
may reflect the type of provider at which treatment was
sought [25]. The nature of interaction does not, however,
explain the treatment received given that overall uptake
of ACT was low from all providers.
It was also surprising to find that only 11% of febrile
patients in the poorest SES received an ACT as recom-
mended, when 29% of respondents from this SES group
attended a public facility and depended on the provider
to recommend treatment. On this point, it is important
to note that very few tests (less than 1% of patients) were
carried out, and the malaria treatment guidelines advise
presumptive treatment of malaria in the absence of a
malaria test [1]. It is, therefore, unclear why so few pa-
tients, especially those attending public facilities received
an ACT. Other studies have highlighted factors that may
influence providers’ decisions to give (or not) an ACT
including fear of stock outs due to inconsistent supply of
ACTs [33] and patients preferences [25].
Although it was found that those of the richest SES
group were more likely to request an antimalarial, only
27% requested an ACT, and far more requested Sulpha-
doxine Pyrimethamine (SP), which is no longer recom-
mended for treating malaria due to extensive resistance
[1]. Similar problems have previously been highlighted,
especially at pharmacies and PMDs where patients com-
monly request specific medicines that are most often
not the recommended ones [25,34]. These suggest there
are also widespread demand side problems with the
uptake of ACT which could be due to the low aware-
ness that ACT is the recommended treatment and the
comparative cost of ACT [35]. The cost of ACTs aver-
ages at $3.6, about three times the cost of SP thus a 2
to 3 days income will be needed to treat a malaria
case with an ACT in Nigeria where over 50% live
below $2 per day [36].
Overall our findings highlight socioeconomic inequi-
ties in timing of treatment seeking for febrile illness and
significant problems with the uptake of ACT. Though
there are no significant differences in the uptake of
ACTs, it cannot be conclusively stated that there is
equity in the use of ACTs given the low uptake by all
SES groups but especially the poorest. Another study
found equity in the use of ACTs among respondents fol-
lowing a free distribution exercise in south-east Nigeria
though the two studies employed different methodolo-
gies [37]. Our findings also suggest that improving the
process of care may not lead to better quality care,
highlighting the need for further exploration of factors
that constitute barriers to uptake of quality malaria
treatment. These findings suggest minimal progress to-
wards achieving timely and equitable coverage of effect-
ive malaria treatment in South-East Nigeria. These
results are in line with other studies from Sub -Saharan
Africa which show better-off individuals are significantly
more likely to obtain antimalarials, and in particular to
obtain effective antimalarials [38,39]. The findings from
this study complement existing literature by providing
new insights into provider-patient interactions, including
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which treatments were requested and received by differ-
ent SES groups. These findings are important for a num-
ber of reasons. First, there is limited evidence on the
process of care, including the specific interactions that
take place between febrile patients and malaria treat-
ment providers and how they influence outcomes of care
for febrile illness, and a better understanding of the care
process is important for overall quality improvements in
malaria treatment. Second, in the current context of
ACT subsidies and targeting for the poor, a body of evi-
dence on the extent and potential barriers of uptake by
different socioeconomic groups is necessary to throw
light on progress towards effective coverage of recom-
mended antimalarials and where more effort is required.
Table 3 Inequalities in patient-provider interaction and treatment received
Poorest 40% Third 20% Fourth 20% Richest 20% All P-value
n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]* n (%) [95% CI]*
N = 362 N = 292 N= 423 N = 565 N = 1642
Nature of interaction
Told HW about fever(a) 312 (75.2) [61.0-85.5] 220 (54.7) [42.1-66.6] 248 (44.1) [36.3-52.2] 255 (36.1) [25.9-47.7] 1035 (44.3) [37.3-51.4] <0.001
HW asked questions about illness(b) 252 (59.9) [47.8-70.9] 184 (41.7) [27.9-56.9] 211 (36.2) [28.6-44.6] 228 (29.7) [20.2-41.3] 875 (35.7) [29.1-43.1] 0.011
Patient was physically examined 116 (21.9) [13.6-33.2] 101 (14.8) [9.2-22.9] 85 (7.6) [4.4-13.1] 101 (9.8) [5.7-16.2] 403 (10.8) [7.9-14.5] 0.031
Patient had temperature taken 98 (16.8) [9.7-27.5] 69 (7.6) [4.6-12.2] 49 (3.4) [2.0-5.7] 54 (4.4) [1.9-9.8] 270 (5.5) [3.9-7.8] 0.007
Patient was tested for malaria 7 (1.0) [0.6-1.7] 6 (1.0) [0.7-1.4] 3 (0.2) [0.1-0.6] 11 (0.8) [0.3-2.3] 27 (0.7) [0.3-1.3] 0.076
Requested a specific medicine 54 (23.3) [13.4-37.4] 85 (49.0) [36.8-61.4] 215 (63.6) [54.7-71.7] 328 (68.1) [57.2-77.4] 682 (60.5) [53.7-66.9] <0.001
For those that requested specific medicine, type of treatment requested N = 676
Antimalarial(c) 27 (69.5) [40.2-88.5) 69 (81.3) [56.6-93.5) 195 (93.7) [86.4-97.2] 295 (89.1) [82.1-93.5) 586 (89.1) [83.1-93.1] 0.057
ACT(c) 6 (26.2) [5.9-66.6] 12 [13.8) [5.6-30.1] 46 (24) [14.7-36.7) 85 (27.0) [18.6-37.5] 149 (24.5) [17.7-32.9] 0.458
Artesunate monotherapy(c) 2 (3.9) [0.5-23.9] 11 (13.8) [5.6-30.4) 39 (18.7) [12.3-27.3] 61 (18.5) [13.4-25.1] 113 (17.6) 13.6-22.4) 0.452
Sulphadoxine Pyrimethamine(c) 13 (32.1) [11.7-62.8] 35 (41.8) [25.0-60.7] 89 (43.4) [33.9-53.4] 126 (37.9) [28.3-48.5] 263 (39.9) [33.0-47.3] 0.741
Other type of antimalarial(c) 6 (7.3) [2.1-22.1] 11 (11.9) [4.8-26.6] 21 (7.7) [3.8-15.0] 23 (5.7) [3.3-9.5] 61 (7.1) [4.9-10.2] 0.395
Antibiotic(c) 7 (7.8) [2.7-20.6] 5 (8.7) [2.0-30.9] 8 (5.0) [1.9-12.1] 21 (6.1) [3.0-12.0] 41 (6.1) [3.5-10.4] 0.775
Antipyretic(c) 19 (31.7) [16.1-52.8] 38 (46.3) [30.4-62.9] 101 (45.9) [35.8-56.4] 162 (50.0) [40.8-59.2] 320 (47.7) [41.1-54.5] 0.563
For those that requested specific medicine, treatment received N = 586
Antimalarial 22 (93.8) [80.8-98.2] 64 (96.5) [86.1-99.2] 190 (98.0) [92.5-99.5] 274 (93.4) [82.0-97.8] 550 (95.3) [89.8-97.9] 0.265
ACT 5 (96.7) [74.5-99.7] 9 (74.4) [22.5-96.7] 43 (95.7) [79.0-99.2] 68 (83.7) [54.3-95.7] 125 (87.3) [67.6-95.8] 0.235
Artesunate monotherapy 1(77.9) [12.6-98.9] 10 (87.8) [27.4-99.3] 37 (94.2) [67.4-99.2] 49 (85.0) [57.2-91.3] 97 (85.0) [68.8-93.6] 0.316
Sulphadoxine Pyrimethamine 11 (94.4) [71.9-99.1] 32 (97.2) [86.3-99.5] 86 (96.3) [83.0-99.3] 120 (96.2) [86.8-99.0] 249 (96.3) [91.4-98.5] 0.948
Other type of antimalarial(c) 3 (66.1 [23.5-92.5] 9 (81.2) [29.4-97.8) 15 (64.7) [30.8-88.3] 17 (75.6) [54.9-85.2] 44 (72.5) [54.9-85.2] 0.789
Antibiotic(c) 5 (70.7) [30.7-92.9] 5 (100) 7 (90.3) [41.5-99.2] 19 (89.2) [42.5-98.9] 36 (90.6) [64.7-98.1] 0.704
Antipyretic(c) 17 (93.2) [70.3-98.8] 36 (89.9) [65.9-97.6] 97 (94.4) [81.1-98.5] 154 (96.2) [90.6-98.5] 304 (94.9) [88.6-97.8] 0.444
Treatment received for all febrile patients N = 1642
Antimalarial 179 (58.1) [46.01-69.3] 184 (71.9) [60.5-81.1] 339 (87.0) [80.7-91.5] 424 (80.1) [72.1-86.2] 1126 (79.3) [74.5-83.4] <0.001
ACT 38 (11.3) [4.6-24.9] 58 (18.1) [10.3-29.8] 91 (22.0) [15.1-30.8] 128 (25.7) [19.3-33.4] 315 (22.4) [17.0-28.8] 0.100
Artesunate monotherapy 10 (3.5) [1.3-9.2] 22 (9.9) [4.8-19.1] 44 (13.2) [8.8-19.3] 82 (16.2) [12.1-21.3] 158 (13.4) [10.6-16.7] 0.053
Sulphadoxine Pyrimethamine 84 (30.7) [20.3-43.6] 82 (35.6) [24.8-48.2] 178 (45.8) [36.4-55.5] 192 (34.6) [26.4-43.9] 536 (37.9) [31.9-44.3] 0.117
Other type of antimalarial 47 (12.6) [7.3-20.9] 27 (10.9) [6.1-18.7] 29 (6.8) [3.6-12.4] 42 (7.4) [4.7-11.5] 145 (8.2) [6.1-10.7] 0.327
Antibiotic 76 (16.0) [10.7-23.3] 39 (10.8) [5.6-19.8] 27 (6.8) [3.8-11.7] 51 (8.4) [5.6-12.5] 193 (8.8) [6.8-11.3) 0.138
Antipyretic 226 (59.4) [49.3-68.7] 167 (56.7) [44.1-68.4] 211 (52.3) [42.6-61.8] 270 (50.8) [43.3-58.3] 875 (52.8) [47.7-57.8] 0.584
For those that received ACT
Received ACT in correct dose 25 (56.5) [17.4-88.9] 47 (77.0) [53.2-90.8] 48 (62.4) [42.6-78.7] 81 (67.7) [45.3-84.2] 201 (67.0) [53.3-78.2] 0.716
Patient knows regimen 20 (48.1) [15.2-82.7] 41 (72.4) [47.8-88.2] 41 (54.3) [31.3-75.6] 67 (59.8) [36.4-79.5] 169 (59.5) [43.7-73.5] 0.655
*Population averaged percentages and corresponding 95% confidence intervals, which have been adjusted for the survey design. (a)Missing one response
(b)Missing two responses (c)Missing 11 responses.
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Lastly, by using the socioeconomic quintiles that apply
to the general population, the findings of this study can
inform interventions to improve malaria treatment in
South-East Nigeria.
One limitation of the study is that the technique used
to determine the SES of the patients attending facilities
is based on an assumption that the household data used
to generate the factor weights is representative of the
local population in the study sites at the time of the exit
survey. The choice of reference group may affect the
precision of the factor weights, and therefore the cut-off
values between different SES categories. However, given
the substantial difference by SES group, choice of refer-
ence group is unlikely to affect the overall trends re-
ported. A second limitation, already noted, concerns the
fact that the respondents seeking treatment tended to be
from higher socio-economic groups with individuals
from the poorest and second poorest quintiles under-
represented in the survey relative to their population
share, which restricts generalisation, in addition, we did
not explore the extent to which patient’s choice of anti-
malarials is a function of their income, this may have
helped to explain the low uptake of ACTs.
In conclusion, the quality of malaria treatment is sub-
optimal for all febrile patients, but worse for the poorest
socioeconomic groups. The fact that the poorest SES
group were more likely to seek treatment at PHC facil-
ities and had greater interaction with the provider did
not translate to better quality care. Our findings high-
light the need for strategies that will improve patient’s
demand for the recommended treatment and encourage
provider adherence to treatment using ACT. These
strategies are fundamental to achieving universal health
coverage and ensuring that the most vulnerable people
are not left behind.
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